InsidersTradesSigma
Follow the 에임드바이오 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares trade on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 에임드바이오 has logged 3 reports. Market capitalisation: €1,552.6bn. The latest transaction was reported on 17 March 2026 (Sale). Among the most active insiders: 인터베스트. All data is openly available.
3
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€69m
2 ops.
Sell Volume
10Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 March 2026
Acerca de 에임드바이오
AimdBio es una empresa que opera en el sector de la salud y farmacéutico, cotizada en el mercado XKRX. Se enfoca en el desarrollo de soluciones biofarmacéuticas innovadoras.